RxDoctor Payments Data

Josef Holme, MD

Family Medicine · Sunset Valley, TXNPI 1699757641

Payments from drug & device makers

$1,620in general payments, 2019–2025

Across 51 payments — averaging $31.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Exact Sciences$43
  • Dexcom, Inc.$35
  • Pfizer$28
  • Abbott$18

What the payments were for

  • Food & beverage$1,620100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk45$1,496
Exact Sciences2$43
Dexcom, Inc.2$35
Pfizer1$28
Abbott1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,620 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$10,315
Medicare patients
34
Services billed
155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide325$379,506
TrulicityDulaglutide186$286,261
JardianceEmpagliflozin95$128,376
MyrbetriqMirabegron82$75,733
EliquisApixaban69$63,455
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog107$61,778
MounjaroTirzepatide51$54,781
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$46,182
LinzessLinaclotide44$32,821
Breo ElliptaFluticasone/Vilanterol53$31,248
FarxigaDapagliflozin Propanediol28$29,691
Tresiba Flextouch U-100Insulin Degludec57$26,832
ProliaDenosumab12$21,469
Spiriva HandihalerTiotropium Bromide18$15,096
XareltoRivaroxaban13$13,601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,496$379,506325 claims
PfizerEliquis$28$63,45569 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sunset Valley

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →